These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 9207928

  • 21. A histopathological investigation on the effect of systemic administration of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the rat mandible.
    Kaynak D, Meffert R, Bostanci H, Günhan O, Ozkaya OG.
    J Periodontol; 2003 Sep; 74(9):1348-54. PubMed ID: 14584869
    [Abstract] [Full Text] [Related]

  • 22. Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone.
    Chambers TJ, Fuller K, Darby JA.
    J Cell Physiol; 1987 Jul; 132(1):90-6. PubMed ID: 3597555
    [Abstract] [Full Text] [Related]

  • 23. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice.
    van Beek ER, Löwik CW, Papapoulos SE.
    Bone; 1997 Apr; 20(4):335-40. PubMed ID: 9108353
    [Abstract] [Full Text] [Related]

  • 24. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
    Vitté C, Fleisch H, Guenther HL.
    Endocrinology; 1996 Jun; 137(6):2324-33. PubMed ID: 8641182
    [Abstract] [Full Text] [Related]

  • 25. Minocycline impairment of both osteoid tissue removal and osteoclastic resorption in a synchronized model of remodeling in the rat.
    Klapisz-Wolikow M, Saffar JL.
    J Cell Physiol; 1996 May; 167(2):359-68. PubMed ID: 8613479
    [Abstract] [Full Text] [Related]

  • 26. Glucocorticoids impair bone resorptive activity and viability of osteoclasts disaggregated from neonatal rat long bones.
    Tobias J, Chambers TJ.
    Endocrinology; 1989 Sep; 125(3):1290-5. PubMed ID: 2759026
    [Abstract] [Full Text] [Related]

  • 27. Osteoblast-mediated effects of zinc on isolated rat osteoclasts: inhibition of bone resorption and enhancement of osteoclast number.
    Holloway WR, Collier FM, Herbst RE, Hodge JM, Nicholson GC.
    Bone; 1996 Aug; 19(2):137-42. PubMed ID: 8853857
    [Abstract] [Full Text] [Related]

  • 28. MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice.
    Mao Z, Zhu Y, Hao W, Chu C, Su H.
    IUBMB Life; 2019 Dec; 71(12):1916-1928. PubMed ID: 31317664
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
    Flanagan AM, Chambers TJ.
    Calcif Tissue Int; 1991 Dec; 49(6):407-15. PubMed ID: 1840176
    [Abstract] [Full Text] [Related]

  • 30. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone.
    Apone S, Lee MY, Eyre DR.
    Bone; 1997 Aug; 21(2):129-36. PubMed ID: 9267687
    [Abstract] [Full Text] [Related]

  • 31. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate.
    Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA.
    Proc Natl Acad Sci U S A; 1996 Apr 02; 93(7):3068-73. PubMed ID: 8610169
    [Abstract] [Full Text] [Related]

  • 32. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone.
    Flanagan AM, Chambers TJ.
    Bone Miner; 1989 Apr 02; 6(1):33-43. PubMed ID: 2526673
    [Abstract] [Full Text] [Related]

  • 33. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.
    Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC.
    J Clin Invest; 2002 Apr 02; 109(8):1041-8. PubMed ID: 11956241
    [Abstract] [Full Text] [Related]

  • 34. Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures.
    Wang Y, Panasiuk A, Grainger DW.
    Mol Pharm; 2011 Aug 01; 8(4):1016-24. PubMed ID: 21186792
    [Abstract] [Full Text] [Related]

  • 35. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M.
    Bone; 1995 Feb 01; 16(2):235-45. PubMed ID: 7756053
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
    Halasy-Nagy JM, Rodan GA, Reszka AA.
    Bone; 2001 Dec 01; 29(6):553-9. PubMed ID: 11728926
    [Abstract] [Full Text] [Related]

  • 37. Effects of transforming growth factor beta 1 on the regulation of osteoclastic development and function.
    Hattersley G, Chambers TJ.
    J Bone Miner Res; 1991 Feb 01; 6(2):165-72. PubMed ID: 1851371
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Giant osteoclast formation and long-term oral bisphosphonate therapy.
    Weinstein RS, Roberson PK, Manolagas SC.
    N Engl J Med; 2009 Jan 01; 360(1):53-62. PubMed ID: 19118304
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of bone resorption by bisphosphonates interferes with orthodontically induced midpalatal suture expansion in mice.
    Koehne T, Kahl-Nieke B, Amling M, Korbmacher-Steiner H.
    Clin Oral Investig; 2018 Jul 01; 22(6):2345-2351. PubMed ID: 29344807
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.